CN

News 2025-10-17

Porton Unveils Porton Up 3.0 Project and Launches Quality Month Initiative, Driving Enterprise-Wide Transformation

Recently, Porton Pharma Solutions held the launch ceremony for Porton Up 3.0 and Porton Quality Month at its Changshou site in Chongqing. Oliver Ju, Chairman and CEO; Yinchun Bai, Senior Vice President; Alan Chen, Vice President; Sophia Meng, Vice President; and Helen Pi, Vice President attended the event alongside employee representatives and key customers, marking the start of a comprehensive upgrade of the company’s core capabilities and compliance management.

Since its founding, Porton has operated under the principles of compliance, continuous improvement, and customer centricity, strengthening its foundation through iterative upgrades to its operating system. From the breakthrough system transformation of Porton Up 1.0, to the deepening of core capabilities in 2.0, and now the holistic uplift of 3.0, each step reflects Porton’s commitment to bringing good medicines to patients sooner and to pursuing high-quality, sustainable growth.





Porton Up 1.0 laid the groundwork for the company’s operating system. By focusing on three core dimensions—Quality, EHS, and Engineering—the company successfully transitioned from an ISO-based system to a GMP-based system. This enabled an expansion from early intermediates and starting materials to GMP products and established Porton as a trusted partner across starting materials, intermediates, and APIs.
In the Porton Up 2.0 phase, the company further upgraded its Quality and EHS systems, established SME teams, and built capabilities in CSV (computerized system validation), CPV (continued process verification), and the application of new technologies. For innovative therapies, Porton developed joint best practices in production excellence to help shorten time-to-market. For commercial products, the company advanced value-sharing and continuous cost-optimization models while maintaining strict quality and risk controls—striking a dynamic balance between quality and efficiency to create greater value for customers.

Amid rapidly evolving market needs and technological change across the global pharmaceutical industry, expectations for quality management and operational excellence are rising. In response, Porton launched Porton Up 3.0. At the kickoff event, the program lead outlined six core pillars—Shop Floor, Documentation, QC Lab, Network Capacity, Investigation, and Mock Inspection—through which the company will drive end-to-end, system-wide enhancements. These initiatives are designed to keep Porton audit-ready at all times while enabling coordinated optimization of the supply network and delivering a step-change in overall site operations.





Mr. Oliver Ju

Chairman and CEO of Porton

“Over two decades, we are deeply grateful to our customers for their trust and to all Porton employees for their dedication,” said Mr. Oliver Ju, Chairman and CEO of Porton. “The Porton Up program is a milestone in our development. From 1.0 to 2.0 and now 3.0, every step has relied on our people and the support of our strategic partner. Management will fully support the execution of Porton Up 3.0, advancing our integrated delivery and quality management toward a first-class operating system characterized by high-standard compliance, high customer satisfaction, and high efficiency.”


Mr. Alan Chen

Vice President, Head of QA

“Porton Up 3.0 is highly significant for Porton,” added Mr. Alan Chen, Vice President, Head of QA. “The dual enhancement of our quality system and operations will enable higher-quality, end-to-end CDMO services for our global partners. To achieve comprehensive, system-wide improvement, our documents and procedures must be put into practice and tightly aligned with shop-floor realities—truly realizing ‘quality through systems, service strengthened by quality.’”


The launch of Porton Up 3.0 is both a new starting point in Porton’s journey to deepen quality management and iterate operational capabilities, and a clear commitment to pursuing high standards and high quality as a leading global CDMO. Building on this milestone, Porton will continue to anchor on its quality management system and leverage stronger technical capabilities, more reliable service, and more efficient collaboration to work in step with pharmaceutical partners worldwide—Enabling the public's early access to good medicines.


Become part of Porton's community to access personalized insights and resources.
Subscribe for the Newsletter
Porton requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and our commitment to protecting your privacy, please review our Legal Disclaimer Terms and Porton Privacy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton's community to access personalized insights and resources.
Submit
By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200